ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag tuberculosis biotech fda business

2022 Top 10 Innovations 
2022 Top 10 Innovations
The Scientist | Dec 12, 2022 | 10+ min read
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
Pharmaceutical And Biotech Firms Taking On Drug-Resistant Microbes
Kathryn Brown | Jun 9, 1996 | 9 min read
Drug-Resistant Microbes As pesky pathogens continue to evolve, new technologies to combat them are emerging, spelling job opportunities for molecular biologists and chemists. OBSTINATE MICROBES: Margaret Rennels cites strains of pneumococcus resistence to two major drugs. At drug and biotech companies across the United States, scientists have set their sights on a most elusive target: drug-resistant microbes. Working in pharmaceutical- biotechnology partnerships, researchers are trying every
Updated Mar 8
A healthcare worker holds up three syringes with clear medicine
To Booster or Not: Scientists and Regulators Debate
Jef Akst | Sep 16, 2021 | 7 min read
President Biden’s planned rollout of additional COVID-19 vaccine doses is set to begin next week, but questions remain about who should get them.
Venture Capital, with a Twist
Ted Agres(tagres@the-scientist.com) | Jul 17, 2005 | 5 min read
Jamie Heywood, chief executive of the Amyotrophic Lateral Sclerosis Therapy Development Foundation (ALSTDF), founded the nonprofit biotech company in 1999 after his brother was diagnosed with ALS.
Updated July 9
Track COVID-19 Vaccines Advancing Through Clinical Trials
The Scientist | Apr 7, 2020 | 10+ min read
Find the latest updates in this one-stop resource, including efficacy data and side effects of approved shots, as well as progress on new candidates entering human studies.
Sorting Made Simpler
Kate Yandell | Dec 1, 2014 | 8 min read
A guide to affordable, compact fluorescence-activated cell sorters
Nice Shot
Megan Scudellari | Jan 1, 2010 | 10+ min read
By Megan Scudellari Nice Shot Why vaccines are pharma’s Next Big Thing. ILLUSTRATION BY Jason Raish Late at night, a feverish young girl shuffled into her father’s room complaining of a sore throat. Maurice Hilleman examined the swollen bumps on his daughter’s neck. It was 1963. She had the mumps, a common childhood disease at the time, caused by a virus that inflames the salivary glands. Most cases are mild, but severe inf
Getting Your Gates
Juhi Yajnik | Nov 1, 2006 | 6 min read
How one company used the growing nonprofit funding pot to jump-start its development program, and how you can do the same.

Run a Search

ADVERTISEMENT